Drug Information

Drug (ID: DG01786) and It's Reported Resistant Information

• Name: D-Glucose
• Synonyms: D-Glc; D-Glucopyranose; D-Glucopyranoside; D-Glucose; Glc; Glucopyranose; Glucopyranoside; Glucose; 2280-44-6; Grape sugar; D-Glcp; Traubenzucker; Glucose solution; (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; Dextrose solution; CHEBI:4167; Corn sugar; Glucopyranose, D-; (3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; DSSTox_CID_2910; Glucodin; Goldsugar; Meritose; 54-17-1; Vadex; Clintose L; CPC hydrate; Roferose ST; Glucose Anhydrous; a-D-Glucose; Clearsweet 95; Staleydex 95M; Staleydex 111; (+)-Glucose; Cerelose 2001; rel-(3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; Tabfine 097(HS); 2h-pyran-2,3,4,5-tetraol; D-Glucopyranose, anhydrous; Liquid glucose; glc-ring; anhydrous glucose; Cartose Cerelose; D-aGlucopyranose; D-glucose-ring; Glucose injection; Glucose 40; Staleydex 130; EINECS 218-914-5; Glc-OH; Meritose 200; nchembio867-comp4; Dextrose, unspecified; Glucose (JP17); starbld0000491; 6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetraol; Anhydrous Glucose ,(S); Glucose, unspecified form; Dextrose, unspecified form; Purified glucose (JP17); Epitope ID:142342; D-(+)-DEXTROSE; DSSTox_RID_76784; DSSTox_RID_82925; DSSTox_GSID_22910; DSSTox_GSID_48729; GTPL4536; CHEMBL1222250; BDBM34103; DTXSID501015215; DTXSID901015217; Tox21_113165; Tox21_200145; AKOS025147374; NSC 287045; CAS-50-99-7; NCGC00166293-01; NCGC00257699-01; BS-48662; CAS-58367-01-4; G0048; (3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-; C00031; D00009; Q37525; Q23905964; N_FULL/O_FULL_10000000000000_GS_656; D-glucose (closed ring structure, complete stereochemistry); WURCS=2.0/1,1,0/[a2122h-1x_1-5]/1/
• Indication:
  In total 1 Indication(s)
  Discovery agent [ICD-11: N.A.]; Investigative; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Diabetic cardiomyopathy [ICD-11: BC43]; [2]
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Type 2 diabetes mellitus [ICD-11: 5A11]; [1]
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Type 2 diabetes mellitus [ICD-11: 5A11]; [3]
• Target: .; NOUNIPROTAC; [1]
• Formula: 1
• IsoSMILES: C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)O
• InChI: InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6 /m1/s1
• InChIKey: WQZGKKKJIJFFOK-GASJEMHNSA-N
• PubChem CID: 5793
• ChEBI ID: CHEBI:4167
• TTD Drug ID: D0C1FY
• VARIDT ID: DR2081
• INTEDE ID: DR00165
• DrugBank ID: DB01914

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-05: Endocrine/nutritional/metabolic diseases

Type 2 diabetes mellitus [ICD-11: 5A11]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Type 2 diabetes mellitus [ICD-11: 5A11.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: HK-2 cells; Kidney; Homo sapiens (Human); CVCL_0302
• In Vivo Model: Male C57BL/6 mice; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR; Western bloting analysis; ELISA assay; RIP experiments assay; RNA pull down assay; Dual luciferase assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: LncRNA MALAT1 interacts with transcription factor Foxo1 to represses SIRT1 transcription in high glucose incubated HK-2 cells, which promotes high glucose-induced HK-2 cells injury.

Key Molecule: X inactive specific transcript (XIST) [3]

• Molecule Alteration: Down-regulation; Interaction
• Resistant Disease: Type 2 diabetes mellitus [ICD-11: 5A11.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: ARPE-19 cells; Eye; Homo sapiens (Human); CVCL_0145
• Experiment for Molecule Alteration: Luciferase assay; qRT-PCR
• Mechanism Description: XIST, likely through competitive binding of hsa-miR-21-5p, provides protection against hyperglycemia-associated injury in human retinal pigment epithelial cells.

ICD-11: Circulatory system diseases

Diabetic cardiomyopathy [ICD-11: BC43]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (NONRATT007560.2) [2]

• Molecule Alteration: Up-regulation; Expression
• Resistant Disease: Diabetic cardiomyopathy [ICD-11: BC43.7]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Rat primary cardiomyocytes; Embryonic heart; Rattus norvegicus (Rat); CVCL_0286
• Experiment for Molecule Alteration: RNA-seq assay
• Experiment for Drug Resistance: Cellular ROS detection assay; Flow cytometry assay
• Mechanism Description: RNA-Seq analysis and functional characterization revealed LncRNA NONRATT007560.2 regulated cardiomyocytes oxidative stress and apoptosis induced by high glucose.

References

• Ref 1: Long non-coding RNA MALAT1 interacts with transcription factor Foxo1 to regulate SIRT1 transcription in high glucose-induced HK-2 cells injuryBiochem Biophys Res Commun. 2018 Sep 5;503(2):849-855. doi: 10.1016/j.bbrc.2018.06.086. Epub 2018 Jul 14.
• Ref 2: RNA-Seq analysis and functional characterization revealed lncRNA NONRATT007560.2 regulated cardiomyocytes oxidative stress and apoptosis induced by high glucoseJ Cell Biochem. 2019 Oct;120(10):18278-18287. doi: 10.1002/jcb.29134. Epub 2019 May 29.
• Ref 3: Long noncoding RNA XIST enhances ethanol-induced hepatic stellate cells autophagy and activation via miR-29b/HMGB1 axisIUBMB Life. 2019 Dec;71(12):1962-1972. doi: 10.1002/iub.2140. Epub 2019 Aug 16.